MISSISSAUGA, Ontario, Oct. 30, 2007 (PRIME NEWSWIRE) -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article by Glenn Wilkins, an AllPennyStocks.com News Reporter, this one discussing Benda Pharmaceutical, Inc. (OTCBB:BPMA), its industry and future prospects.
Wilkins notes that marvelous advances have been made in recent memory in the fight against cancer. One of the most noteworthy has come from behind what we used to call the "Bamboo Curtain," in a modern China more accustomed than before to opening medical and commercial gates to the West.
It's called Gendicine, the world's first commercialized gene therapy medicine for the treatment of cancer, and the flagship medicine among the dozens distributed by Benda Pharmaceutical.
Benda, headquartered in North America in the Pacific Northwest and British Columbia, is a China-based pharmaceutical company, a pure play on explosive Chinese drug company spending and the global search for a cancer cure. Benda is involved in the production of both conventional as well as cutting edge gene therapy Chinese medicines. The company owns and operates five plants, combining to produce more than 30 medicines and medicine ingredients.
The full version of this special report on BPMA can be found at:
http://www.allpennystocks.com/aps_us/special_reports/archives/102907.asp
About AllPennyStocks.com:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and U.S. site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs weekly stocks to watch, has a weekly market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, Nasdaq and OTCBB, and much more information for the average investor.
Although the majority of AllPennyStocks.com reports are independent, it has received compensation for carrying the report on Benda Pharmaceutical, Inc. (OTCBB:BPMA), the compensation is seventeen thousand seven hundred and fifty dollars by the company for its efforts in presenting the BPMA profile on its web site and distributing it to its database of subscribers as well as other services. This creates an inherent conflict of interest and readers are encouraged to view the main disclaimer at http://www.allpennystocks.com/aps_us/company_spotlights/archives/bpma.asp.